- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Adrianne Appel2022-12-21T20:21:00
Medical technology company BioTelemetry and its heart rate monitoring subsidiary CardioNet agreed to pay more than $44.8 million to settle allegations they violated U.S. federal health laws by improperly billing Medicare and other federal programs for heart monitoring and cardiac test analyses performed by a company in India.
Federal law requires services for patients of federal health programs, like Medicare, be provided within the United States to be reimbursed.
The trouble began for BioTelemetry in 2013, when it contracted with a group in India to conduct Holter-associated monitoring and interpret the results. The Holter heart monitor is designed to detect faulty and dangerous heart rhythms related to heart attacks and poor heart function.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
Wireless medical technology company BioTelemetry and its subsidiary LifeWatch Services agreed to pay more than $14.7 million as part of a settlement with the Department of Justice regarding alleged false claims submitted to federal healthcare programs.
Spacelabs Healthcare agreed to pay $2.5 million as part of a settlement with the Department of Justice resolving allegations it overcharged the U.S. Department of Veterans Affairs for medical devices.
Penalties assessed for violations of the False Claims Act topped $2.2 billion during fiscal year 2022, less than half the mark the Department of Justice reached the previous year.
USAA Federal Savings Bank has been hit with its third cease and desist order from the Treasury Department’s Office of the Comptroller of the Currency in the past five years for failing to correct unsafe and unsound banking practices.
Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.
The Securities and Exchange Commission charged bankrupt fashion retailer Express with failing to disclose nearly $1 million in perks to a former chief executive, but did not levy a financial penalty thanks to its cooperation, the SEC said.
